

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS	
P.O. Hox 1450 Alexandria, Virginia 22313-1450	
www.uspto.gov	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/405,735	09/24/1999	GERALD B. PIER	B0801/7155	9816	
75	590 07/01/2003				
HELEN C LOCKHART			EXAMINER		
600 ATLANTI			SIEW, JEFFREY		
BOSTON, MA	BOSTON, MA 02210		ART UNIT	PAPER NUMBER	
			1637	21	
			DATE MAILED: 07/01/2003	DATE MAILED: 07/01/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
· · · · · · · · · · · · · · · · · · ·	09/405,735	PIER, GERALD B.				
Office Action Summary	Examiner	Art Unit				
	Jeffrey Siew	1637				
The MAILING DATE of this communication a Period for Reply	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)⊠ Responsive to communication(s) filed on 22	2 May 2003 .					
	This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>14-43</u> is/are pending in the applica	tion.					
4a) Of the above claim(s) is/are withdr	awn from consideration.					
5)☐ Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>14-43</u> is/are rejected.						
7)☐ Claim(s) is/are objected to.						
8)☐ Claim(s) are subject to restriction and	or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on	is: a)□ approved b)□ disappr	oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
Certified copies of the priority document	nts have been received in Applica	tion No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domes	stic priority under 35 U.S.C. § 119	(e) (to a provisional application).				
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office A	Action Summary	Part of Paper No. 21				

'Application/Control Number: 09/405,735

Art Unit: 1637

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 14- 43 are rejected under 35 U.S.C. 102(a) as being anticipated by Masoud et al (J. of Bacteriology Dec. 1995 pp. 6718-6726).

Masoud et al teach the isolation of lipopolysaccharide core of <u>P. aeruginosa</u> (see whole doc.). They teach that the core contains an alanine (see Table 2 & Figure 8 & 9). Figure 9 appears to teach the lipid core structure.

The term "bioactive agent" and "covalent conjugate" are interpreted broadly to include the polysaccharide portions of the lipopolysaccharide.

The response filed 5/22/03 strictly bases its argument that Masoud et al do not teach bioactive agent or non toxic lipid. The response states that Masoud et al do not teach bioactive agents as set forth in page 13 of the specification. Limitations in the specification are not read into the claims. Masoud et al also teach portions of lipid core that are covalently bound to polysaccharide and vaccine derivatives of core glycolipid antigen (see Table 2). Moreover, the response merely states that Masoud et al do not teach non toxic lipid portions. As these structures are within vaccine preparations, they are therefore do not exhibit toxicity.

Art Unit: 1637

It is recommended that more specificity be added to the type of bioactive agent as an avenue toward possible allowable subject matter, provided proper support lies in the specification.

SUMMARY

2. No claims allowed.

CONCLUSION

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is Jeffrey. Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner is on flex-time schedule and can best be reached on weekdays from 6:30 a.m. to 3 p.m. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703)-308-1119.

Any inquiry of a general nature, matching or filed papers or relating to the status of this application or proceeding should be directed to the Tracey Johnson for Art Unit 1637 whose telephone number is (703)-305-2982.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official

*Application/Control Number: 09/405,735

Art Unit: 1637

Page 4

Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Before Final FAX (703) 872-9306 or After Final FAX (703) 30872-9307.

JEFFREY SIEW PRIMARY EXAMINER

June 29, 2003